TransCode Therapeutics Stock Jumps 21% On Polynoma Acquisition

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) shares surged 20.70 percent, rising $2.53 to $14.75 on Wednesday, after announcing the acquisition of Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage melanoma vaccine candidate. The company also secured a $25 million investment from CK Life Sciences to fund its Phase 2 trial of lead microRNA therapy TTX-MC138.

The stock is currently trading at $14.23, compared with a previous close of $12.22 on the Nasdaq. Shares opened at $18.91 and have traded between $13.18 and $20.99 so far today, with trading volume reaching 7.1 million shares, above the average of 88,000.

Over the past 52 weeks, TransCode shares have ranged between $6.15 and $739.20.